- Pharmaceutical giant After years of not paying nominal maintenance fees, it will lose patent protection for its Semaglutide sold in Canada, which has not paid nominal maintenance fees until it became a huge drug for diabetes and obesity. science Report. Novo Nordisk Canada’s drug revenue is billions, but patent protection will end next year.
According to a recent recent one, the Danish pharmaceutical giant had the opportunity to maintain its patents in Canada without paying a small fee before Semaglutide became a blockbuster drug for Novo Nordisk. Report science.
The drug is sold in the form of Ozes and Wagovi, and after it exploded in the past few years, it has made a lot of money Influences Denmark’s currency and interest rates.
To retain Canada’s Semaglutide patent, the company paid only 250 Canadian dollars in annual fees (about $185). Although it paid the amount in 2018 science Reports say this is not the second year.
The Canadian government has offered Novo Nordisk another opportunity to retain patents, this time at an additional cost to total $450 ($331).
“To prevent layoffs of patents, the amounts listed above (including required maintenance fees and deferred payment fees must be paid within one year’s grace period after the date of filing),” Letters from regulators It said that the anniversary will be set as March 20, 2019.
Manufacturers of general medicines have noticed science Noting that the company’s latest comment has been proposed, which has introduced the launch of the GLP-1 in Canada next year and is expected to be approved sometime in the first quarter of its exclusive expiration.
“Interesting market. Novo never filed a patent in Canada. Never know why.” Sandoz CEO Richard Saynor Tell Endpoint News Earlier this month. “I’m sure someone lost their job, but that’s OK. It’s the second largest Semaglutide market in the world.”
In a statement wealthNovo Nordisk said there was no misunderstanding of its patent maintenance fees in Canada and declined to comment on other drug manufacturers’ plans.
“All intellectual property decisions are carefully considered globally,” the company added. “The exclusive period of medicines ends with part of their normal life cycle and general therapy.”
The company confirmed that the protection submitted by Canadian ceragglutide regulation will expire in 2026.
Meanwhile, according to the company’s recent recent annual report.
Last year, Novo Nordisk’s global Ozempic sales were approximately $19 billion, and about $9 billion in Wegovy sales. In Canada, there retail pharmacies booked Ozempic with sales of $2.5 billion.
This story was originally fortune.com
